Procaps Group Sa Stock Today

PROC Stock  USD 1.50  0.05  3.45%   

Performance

Good

 
Weak
 
Strong

Odds Of Distress

Average

 
High
 
Low
Procaps Group is trading at 1.50 as of the 17th of February 2025, a 3.45% up since the beginning of the trading day. The stock's open price was 1.45. Procaps Group has 51 percent odds of going through some form of financial distress in the next two years but had a very good returns during the last 90 days. The performance scores are derived for the period starting the 18th of January 2025 and ending today, the 17th of February 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
30th of September 2021
Category
Healthcare
Classification
Health Care
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company was founded in 1977 and is based in Luxembourg, Luxembourg. Procaps Group is traded on NASDAQ Exchange in the United States. The company has 112.82 M outstanding shares of which 113.88 K shares are at this time shorted by private and institutional investors with about 2.91 trading days to cover. More on Procaps Group SA

Moving against Procaps Stock

  0.63JNJ Johnson JohnsonPairCorr
  0.63AMGN Amgen IncPairCorr
  0.46INVA InnovivaPairCorr
  0.45AMCCF Amcor plcPairCorr
  0.35APVO Aptevo TherapeuticsPairCorr
  0.35ALC Alcon AG Sell-off TrendPairCorr

Procaps Stock Highlights

Executive ChairmanCPA CPA
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover1.011.02
Slightly Down
Pretty Stable
Gross Profit Margin0.460.53
Fairly Down
Slightly volatile
Net Debt258.6 M218.6 M
Fairly Up
Slightly volatile
Total Current Liabilities287.2 M423.6 M
Way Down
Slightly volatile
Non Current Liabilities Total80.1 M84.3 M
Notably Down
Slightly volatile
Total Assets445.4 M529.2 M
Fairly Down
Slightly volatile
Total Current Assets262 M342.1 M
Way Down
Slightly volatile
Total Cash From Operating Activities40.6 M56.7 M
Way Down
Slightly volatile
Debt Levels
Procaps Group can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Procaps Group's financial leverage. It provides some insight into what part of Procaps Group's total assets is financed by creditors.
Liquidity
Procaps Group SA currently holds 285.94 M in liabilities with Debt to Equity (D/E) ratio of 6.02, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Procaps Group SA has a current ratio of 1.51, which is within standard range for the sector. Note, when we think about Procaps Group's use of debt, we should always consider it together with its cash and equity.

Change To Inventory

(4.33 Million)
Procaps Group SA (PROC) is traded on NASDAQ Exchange in USA and employs 5,500 people. Procaps Group is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 113.95 M. Procaps Group SA conducts business under Biotechnology sector and is part of Health Care industry. The entity has 112.82 M outstanding shares of which 113.88 K shares are at this time shorted by private and institutional investors with about 2.91 trading days to cover. Procaps Group SA currently holds about 37.55 M in cash with 62.99 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.37.
Check Procaps Group Probability Of Bankruptcy
Ownership Allocation
Procaps Group owns a total of 112.82 Million outstanding shares. Procaps Group holds majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 83.02 pct. of Procaps Group SA outstanding shares that are owned by insiders implies they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Procaps Ownership Details

Procaps Stock Institutional Holders

InstituionRecorded OnShares
Exome Asset Management Llc2024-09-30
126.9 K
Geode Capital Management, Llc2024-09-30
28.9 K
Activest Wealth Management2024-12-31
10 K
Morgan Stanley - Brokerage Accounts2024-09-30
100.0
State Street Corp2024-09-30
0.0
Royal Bank Of Canada2024-09-30
0.0
Pineridge Advisors Llc2024-12-31
0.0
View Procaps Group Diagnostics

Procaps Group SA Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Procaps Group market risk premium is the additional return an investor will receive from holding Procaps Group long position in a well-diversified portfolio.

Procaps Stock Against Markets

When determining whether Procaps Group SA offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Procaps Group's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Procaps Group Sa Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Procaps Group Sa Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Procaps Group SA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Procaps Group. If investors know Procaps will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Procaps Group listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.64)
Earnings Share
0.66
Revenue Per Share
4.097
Quarterly Revenue Growth
0.073
Return On Assets
0.0628
The market value of Procaps Group SA is measured differently than its book value, which is the value of Procaps that is recorded on the company's balance sheet. Investors also form their own opinion of Procaps Group's value that differs from its market value or its book value, called intrinsic value, which is Procaps Group's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Procaps Group's market value can be influenced by many factors that don't directly affect Procaps Group's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Procaps Group's value and its price as these two are different measures arrived at by different means. Investors typically determine if Procaps Group is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Procaps Group's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.